Statement Of Comprehensive Income [Abstract]

Sopharma AD - Filing #6022429

Concept	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31
Statement of comprehensive income [abstract]
Profit (loss)	71 121 BGN	—	—	76 333 BGN	71 121 BGN	5 212 BGN	—	2 207 BGN	—	—	—	89 496 BGN	91 703 BGN	89 496 BGN
Other comprehensive income [abstract]
Components of other comprehensive income that will be reclassified to profit or loss, before tax [abstract]
Exchange differences on translation [abstract]
Gains (losses) on exchange differences on translation of foreign operations, before tax	—	—	—	4 637 BGN	—	—	—	—	—	—	—	—	799,000 BGN	—
Share of other comprehensive income of associates and joint ventures accounted for using equity method that will be reclassified to profit or loss, before tax	—	—	—	790,000 BGN	—	—	—	—	—	—	—	—	3 708 BGN	—
Income tax relating to components of other comprehensive income that will not be reclassified to profit or loss [abstract]
Income tax relating to components of other comprehensive income that will not be reclassified to profit or loss	—	—	—	99,000 BGN	—	—	—	—	—	—	—	—	1 150 BGN	—
Other comprehensive income	6 011 BGN	8 92 BGN	1 047 BGN	5 868 BGN	1 355 BGN	143,000 BGN	5 427 BGN	4 7 9 BGN	3 55 BGN	3 367 BGN	9 485 BGN	12 474 BGN	11 995 BGN	2 3 BGN
Comprehensive income	65 110 BGN	8 92 BGN	1 047 BGN	70 465 BGN	72 476 BGN	5 355 BGN	5 427 BGN	1 728 BGN	3 55 BGN	3 367 BGN	9 485 BGN	101 970 BGN	103 698 BGN	89 473 BGN
Comprehensive income attributable to [abstract]
Comprehensive income, attributable to owners of parent	—	—	—	65 110 BGN	—	—	—	—	—	—	—	—	101 970 BGN	—
Comprehensive income, attributable to non-controlling interests	—	—	—	5 355 BGN	—	—	—	—	—	—	—	—	1 728 BGN	—